Clinical trials: Phase 2
Plague, Pneumonic, Plague
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
Phase 2, Randomized, Active-Controlled, Observer-Blinded, Multicenter Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine with CpG 1018® Adjuvant Compared with rF1V Vaccine in Adults 18 to 55 Years of Age
- Conditions
- Plague, Pneumonic, Plague, Vaccine-Preventable Diseases
- Trial name
- NCT05506969
- Testing
- rF1V-1018, rF1V vaccine
- Where
- 6 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Clostridium Difficile Associated Disease
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
This study will investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.
- Trial name
- NCT02117570
- Testing
- Clostridium difficile vaccine
- Where
- 12 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pfizer
Herpes Zoster, Herpes Zoster Vaccine
A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
The purpose of this study was a long-term follow-up of the two studies 110390 and 113077 (ZOSTER-006/022) to assess the efficacy, safety, and immunogenicity persistence of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine…
- Trial name
- NCT02723773
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 161 sites in United States, Australia and 16 more
- Volunteers
- 7,539 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adverse Event Following Immunisation
A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children
Sabin 2 will be withdrawn from routine use globally from April 2016 as per the SAGE recommendations at the time of writing this protocol.
- Trial name
- M2-ABMG (NCT02521974)
- Testing
- SABIN monovalent OPV2
- Volunteers
- 164 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Acne Vulgaris
Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris
study designed to assess the safety, tolerability, and efficacy of IDP-120 Gel and IDP-120 Vehicle Gel
- Trial name
- NCT03664739
- Testing
- IDP-120 Gel, IDp-120 Vehicle Gel
- Where
- 30 sites in United States, Canada
- Volunteers
- 608 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Neurofibromatosis 2, Meningioma
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
The goal of this clinical research study is to learn if the study drug AZD2014 can shrink growing or symptomatic meningiomas.
- Trial name
- NCT02831257
- Testing
- AZD2014
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Chronic Allergic Conjunctivitis
OTX-14-001: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02062905
- Testing
- Dexamethasone
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ocular Therapeutix, Inc.
Zika Virus
Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)
This study will include 4 cohorts of 14 ZIKV and DENV-naïve female and male subjects, 18 - 40 years of age (total: up to 56 subjects).
- Trial name
- NCT05123222
- Testing
- ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis B
Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine
The purpose of this study is to find out if a new investigational hepatitis B virus vaccine, HEPLISAV™, is safe and effective compared with Engerix-B® vaccine in subjects 11-55 years old.
- Trial name
- NCT00435812
- Testing
- Engerix-B
- Where
- 18 sites in Canada, Germany
- Volunteers
- 2,428 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Safety, Pharmacokinetics, Pharmacodynamics, Food Effect
Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of AZD7986 in healthy volunteers
- Trial name
- NCT02303574
- Testing
- AZD7986, oral solution, 1 to 50 mg/mL
- Where
- United Kingdom
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2
This study is designed to determine the pharmacokinetic (PK) profile of a single oral dose of PBT2 administered to healthy volunteers in the presence and absence of food.
- Trial name
- NCT02107313
- Testing
- Fed Cohort PBT2, Fasted Cohort PBT2
- Where
- Australia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Prana Biotechnology Limited
Healthy
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
The purpose of this study is to assess the safety of Takeda's tetravalent dengue vaccine (TDV) (previously DENVax) administered subcutaneously in healthy adults and children.
- Trial name
- NCT01511250
- Testing
- TDV
- Where
- 8 sites in Colombia, Puerto Rico and 2 more
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Takeda
SARS-CoV-2, COVID-19
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
The purpose of Part A of this study is to assess the immune response and safety of a booster dose of investigational COVID-19 mRNA vaccines in healthy adults.
- Trial name
- NCT05960097
- Testing
- CV0701 mRNA COVID-19 Vaccine (Low dose), CV0701 mRNA COVID-19 Vaccine (Medium dose), CV0701 mRNA COVID-19 Vaccine (High dose)
- Where
- 17 sites in United States, Australia
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults
The purpose of this study is to evaluate the safety and immune response of two-doses of GSK Biologicals' candidate influenza vaccine GSK 1557484A with or without adjuvant in adults.
- Trial name
- NCT00510874
- Testing
- Pumarix™, Pandemrix ™
- Where
- 10 sites in United States, Canada
- Volunteers
- 780 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
MENINGOCOCCAL INFECTION
A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children.
- Trial name
- NCT02531698
- Testing
- Bivalent rLP2086 Vaccine, Licensed pediatric hepatits A vaccine, Normal Saline
- Where
- 15 sites in Finland, Poland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Pfizer
Age-Related Macular Degeneration
Alpha Lipoic Acid in Geographic Atrophy
Because of its iron-chelating and antioxidant properties, alpha lipoic acid may be a treatment for geographic atrophy (GA) secondary to age-related macular degeneration.
- Trial name
- ALA (NCT02613572)
- Testing
- alpha lipoic acid
- Where
- 5 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Hypogonadism
A Bioequivalence Study of Testosterone Cypionate in Hypogonadal Males
This is an open-label, 2-treatment, 2-period, single dose (200 mg, IM) cross-over study, 2-part design to evaluate the bioequivalence (BE) of a reformulated presentation (test) of testosterone cypionate solution for injection…
- Trial name
- NCT03792477
- Testing
- Test formulation, Reference formulation
- Where
- 2 sites in United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Pfizer
Posttraumatic Stress Disorder
MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD
The goal of this clinical trial is to learn if cognitive-behavioral conjoint therapy (CBCT) in combination with MDMA-assisted therapy is safe and effective in people with chronic PTSD and their partners.
- Trial name
- NCT02876172
- Testing
- MDMA, CBCT, Therapy
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Resilient Pharmaceuticals
Healthy Japanese Young and Elderly Male and Non-fertile Female Volunteers
A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers
This study consists of two parts, ie, single dose part with young healthy subjects (Part 1) and single and multiple dose part with elderly healthy subjects (Part 2), to assess the safety, tolerability, pharmacokinetics and…
- Trial name
- NCT02005211
- Testing
- AZD3293
- Where
- Japan
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers, Norovirus, Prevention
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP), Aluminum Hydroxide and MPL adjuvant (3-O-desacyl-4'-monophosphoryl lipid A) for…
- Trial name
- NOR-107 (NCT02038907)
- Testing
- Hepatitis A Vaccine, Norovirus Bivalent VLP Vaccine
- Where
- 2 sites in Belgium
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Takeda